Sunshine 2 Study for Women With Diabetes
Primary Purpose
Diabetes, Depression, Quality of Life
Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Vitamin D3
Vitamin D3 comparator
Sponsored by

About this trial
This is an interventional treatment trial for Diabetes focused on measuring Vitamin D, Diabetes, Self-Management, Depression, Women
Eligibility Criteria
Inclusion Criteria:
- Women age 21 and older
- Objective evidence of depressive symptoms at the screening and baseline visits
- Diagnosis of type 2 diabetes currently being treated by a healthcare provider
- Blood vitamin D level less than 32 nanograms-per-deciliter (32 ng/dl)
Exclusion Criteria:
- Current alcohol or substance use disorder
- Any unstable or severe psychiatric disease including diagnoses of schizophrenia, bipolar affective disorder, dementia, delirium, or other psychotic disorder
- Severe complications of diabetes, such as blindness and/or amputation
- Any malabsorption disorder, such as Crohn's disease and/or celiac sprue
- Elevated serum calcium level deemed significant by the Principal Investigator
- Use of 1,000 or more international units daily vitamin D 60 days before enrollment and unwillingness to discontinue vitamin D supplementation 30 days before enrollment.
- Use of St. John's Wort and unwillingness to discontinue St. John's Wort three weeks prior to enrollment.
- Participants who are pregnant, nursing, or planning to become pregnant during the study.
- Baseline systolic blood pressure (SBP) greater than 160 millimeters of mercury (mmHG) or diastolic blood pressure (DBP) greater than 100 mmHG.
- Other serious medical conditions (e.g., cancer, multiple sclerosis, etc.) deemed clinically significant by the Principal Investigator
Sites / Locations
- Loyola University Medical Center
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Vitamin D3
Vitamin D3 comparator
Arm Description
50,000 international units (IUs) weekly Vitamin D3
5,000 international units (IUs) of a weekly Vitamin D3 comparator
Outcomes
Primary Outcome Measures
Change in Center for Epidemiologic Studies Depression (CES-D) Score From Baseline (Month 0) to Month 6 for the High Dose Cohort Versus Low Dose Cohort
The Center for Epidemiologic Studies Depression (CES-D) is a self-report questionnaire assessing frequency and severity of depression symptoms. Raw scores range from 0 to 60, where higher scores indicate worse mood. For each participant, her baseline CES-D score is subtracted from her month 6 CES-D score to create a CES-D change score.
Secondary Outcome Measures
Change in Problem Areas in Diabetes (PAIDS) Score From Baseline (Month 0) to Month 6 for the High Dose Cohort Versus Low Dose Cohort
The Problem Areas in Diabetes (PAIDS) score is a self-report questionnaire that assesses diabetes burden and treatment. Scores range from 0 to 100, where higher scores indicate greater distress. For each participant, her baseline PAID score is subtracted from her month 6 PAID score to create a PAID change score.
Change in Systolic Blood Pressure From Baseline (Month 0) to Month 6 for the High Dose Cohort Versus Low Dose Cohort
Systolic blood pressure is measured in millimeters of mercury (mmHg). For each participant, her baseline systolic blood pressure is subtracted from her month 6 systolic blood pressure to create a systolic blood pressure change score.
Change in Diastolic Blood Pressure From Baseline (Month 0) to Month 6 for the High Dose Cohort Versus Low Dose Cohort
Diastolic blood pressure is measured in millimeters of mercury (mmHg). For each participant, her baseline diastolic blood pressure is subtracted from her month 6 diastolic blood pressure to create a diastolic blood pressure change score.
Full Information
NCT ID
NCT01904032
First Posted
July 17, 2013
Last Updated
March 30, 2022
Sponsor
Loyola University
Collaborators
National Institutes of Health (NIH), National Institute of Nursing Research (NINR)
1. Study Identification
Unique Protocol Identification Number
NCT01904032
Brief Title
Sunshine 2 Study for Women With Diabetes
Official Title
Vitamin D Supplement to Women With Type 2 Diabetes
Study Type
Interventional
2. Study Status
Record Verification Date
March 2022
Overall Recruitment Status
Completed
Study Start Date
November 21, 2013 (Actual)
Primary Completion Date
November 11, 2017 (Actual)
Study Completion Date
August 31, 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Loyola University
Collaborators
National Institutes of Health (NIH), National Institute of Nursing Research (NINR)
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This is a randomized clinical trial (RCT) to determine the effectiveness of vitamin D3 supplementation on depressive symptoms, self-management, and blood pressure in approximately 180 adult women with type 2 diabetes who have significant depressive symptoms. Consenting adult women who are eligible to participate will be randomly assigned to either a weekly dose of 50,000 international units of vitamin D3 supplementation or a matching weekly active comparator of 5,000 international units of vitamin D3 for six months. Participants will complete approximately four in-person study visits and several telephone visits throughout the six month trial period, where the researchers will assess depressive symptoms, diabetes self-management, and systolic blood pressure.
Detailed Description
The primary aim of this study is to determine the effect of vitamin D supplementation on depressive symptoms, self-management, and systolic blood pressure compared to placebo. The hypothesis is that women receiving vitamin D supplementation will report fewer depressive symptoms, increased diabetes self- management mediated by depression improvement, and will have a lower systolic blood pressure compared to those taking placebo at three and six months follow-up.
The secondary aim is to explore the mechanistic effect of vitamin D supplementation on inflammatory biomarkers and their association with depression. Here, the hypothesis is that women receiving vitamin D supplementation will have a decrease in inflammatory biomarkers which will be associated with fewer depressive symptoms compared to those taking placebo at three and six months follow-up.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes, Depression, Quality of Life
Keywords
Vitamin D, Diabetes, Self-Management, Depression, Women
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Model Description
Participants are randomized to either 50,000 international units of weekly vitamin D3 or to 5,000 international units of weekly vitamin D3 using a 1:1 allocation
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
265 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Vitamin D3
Arm Type
Experimental
Arm Description
50,000 international units (IUs) weekly Vitamin D3
Arm Title
Vitamin D3 comparator
Arm Type
Active Comparator
Arm Description
5,000 international units (IUs) of a weekly Vitamin D3 comparator
Intervention Type
Drug
Intervention Name(s)
Vitamin D3
Other Intervention Name(s)
Cholecalciferol
Intervention Description
50,000 international units (IUs) weekly Vitamin D3
Intervention Type
Drug
Intervention Name(s)
Vitamin D3 comparator
Other Intervention Name(s)
Cholecalciferol
Intervention Description
5,000 international units (IUs) of a weekly Vitamin D3 comparator
Primary Outcome Measure Information:
Title
Change in Center for Epidemiologic Studies Depression (CES-D) Score From Baseline (Month 0) to Month 6 for the High Dose Cohort Versus Low Dose Cohort
Description
The Center for Epidemiologic Studies Depression (CES-D) is a self-report questionnaire assessing frequency and severity of depression symptoms. Raw scores range from 0 to 60, where higher scores indicate worse mood. For each participant, her baseline CES-D score is subtracted from her month 6 CES-D score to create a CES-D change score.
Time Frame
Baseline and 6 months
Secondary Outcome Measure Information:
Title
Change in Problem Areas in Diabetes (PAIDS) Score From Baseline (Month 0) to Month 6 for the High Dose Cohort Versus Low Dose Cohort
Description
The Problem Areas in Diabetes (PAIDS) score is a self-report questionnaire that assesses diabetes burden and treatment. Scores range from 0 to 100, where higher scores indicate greater distress. For each participant, her baseline PAID score is subtracted from her month 6 PAID score to create a PAID change score.
Time Frame
Baseline and 6 months
Title
Change in Systolic Blood Pressure From Baseline (Month 0) to Month 6 for the High Dose Cohort Versus Low Dose Cohort
Description
Systolic blood pressure is measured in millimeters of mercury (mmHg). For each participant, her baseline systolic blood pressure is subtracted from her month 6 systolic blood pressure to create a systolic blood pressure change score.
Time Frame
Baseline and 6 months
Title
Change in Diastolic Blood Pressure From Baseline (Month 0) to Month 6 for the High Dose Cohort Versus Low Dose Cohort
Description
Diastolic blood pressure is measured in millimeters of mercury (mmHg). For each participant, her baseline diastolic blood pressure is subtracted from her month 6 diastolic blood pressure to create a diastolic blood pressure change score.
Time Frame
Baseline and 6 months
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Women age 21 and older
Objective evidence of depressive symptoms at the screening and baseline visits
Diagnosis of type 2 diabetes currently being treated by a healthcare provider
Blood vitamin D level less than 32 nanograms-per-deciliter (32 ng/dl)
Exclusion Criteria:
Current alcohol or substance use disorder
Any unstable or severe psychiatric disease including diagnoses of schizophrenia, bipolar affective disorder, dementia, delirium, or other psychotic disorder
Severe complications of diabetes, such as blindness and/or amputation
Any malabsorption disorder, such as Crohn's disease and/or celiac sprue
Elevated serum calcium level deemed significant by the Principal Investigator
Use of 1,000 or more international units daily vitamin D 60 days before enrollment and unwillingness to discontinue vitamin D supplementation 30 days before enrollment.
Use of St. John's Wort and unwillingness to discontinue St. John's Wort three weeks prior to enrollment.
Participants who are pregnant, nursing, or planning to become pregnant during the study.
Baseline systolic blood pressure (SBP) greater than 160 millimeters of mercury (mmHG) or diastolic blood pressure (DBP) greater than 100 mmHG.
Other serious medical conditions (e.g., cancer, multiple sclerosis, etc.) deemed clinically significant by the Principal Investigator
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Susan Penckofer, Ph.D., R.N.
Organizational Affiliation
Loyola University Chicago Health Sciences Division
Official's Role
Principal Investigator
Facility Information:
Facility Name
Loyola University Medical Center
City
Maywood
State/Province
Illinois
ZIP/Postal Code
60153
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Sunshine 2 Study for Women With Diabetes
We'll reach out to this number within 24 hrs